Bristol Myers Squibb Holdings Ireland & Anr vs.sanjay Jain & Anr

Decided On : Oct-18-2016

Court : Delhi

LAW: Plaintiff No.2, Section 43 Patent Act 8, Section 11A, Section 43(2, Section 48, Section 48, the Patents Act

DATE: 18th October,, 2016, 14.3.2016, 6312, 2004, the year 1989, 1887, September 19, 2001, April 12, 2000 April 15, 1999 March 4, 2005 Date, November 16, 2006 Notification, under May 18, 2007, address.10, 15 years, 4th March 2005, 18th May 2007, 4309, February, 2005, 28th June, 2006, August 30, 2006, the past five years, October, 2015, one or two weeks, 1 September, 2015, 7th July 2014, the years 2008 to 2015, 24, 1970, 2004, 4 SCC50has, 1970, 46, 2005, 2003, 2008, 31, 2005, 29.03.2006, 32, 46, 2016

ORG: BRISTOL MYERS SQUIBB HOLDINGS IRELAND & ANR, JAIN & ANR Through, CPC, Bristol-Myers Squibb Holdings Ireland, Bristol-Myers Squibb India Private Limited, Bristol-Myers Squibb Co., Bristol-Myers Company, Squibb Corporation, Bristol-Myers Squibb Co., BMS, DASATINIB, DASATINIB, the United States CS(COMM, Bristol-Myers Squibb Co., Assignment, the Register of Patents, the Indian Patent Office, DASATINIB, the International Non-proprietary Name, INN, CML, DASATINIB, CML, TKI, CML, CML, CML, TKI, DASATINIB, DASATINIB, CML, DASATINIB, DASATINIB, CML, DASATINIB, INN, the Intellectual Property Appellate Board, DASATINIB, the Indian Patent Office, DASATINIB, DASATINIB, DASATINIB, granted.14, the US Food and Drug Administration, DASATINIB, the Drug Controller General of India, BMS, the Sprycel Access Program, India Journal of Cancer, Patient Access Program, M/s Cyno Medicaments, Cyno Pharmaceutical Limited, http://www.cynoindia.com/en/, DASATINIB, DASATINIB, CS(COMM) 197/2016, Journal, Exhibit PW-1/6, WHO Drug Information, Sprycel, Exhibit PW-1/10, BMS‟s PAP, PAP, DASACY, Defendants, Exhibit PW-1/17, Exhibit, the Suprme Court, Court, Time Incorporated, Lokesh Srivastava & Anr, CS(COMM), Court, Court, Court, Microsoft Corporation, Rajendra Pawar & Anr, Court, Plaintiff, Court, Judicial Process, Court, Court

PERSON: Praveen Anand, Nischal Anand, Aman Taneja, No.203937, Joint Registrar, Jitender Tyagi, William McLaren Bristol, John Ripley Myers, Edward Robinson Squibb, Ph+, immunologic disorders, DASATINIB, DASATINIB, DASATINIB, DASATINIB, Exhibit PW-1/1, Exhibit PW-1/5, Exhibit PW-1/7, www.Cyno.net.in, Sanjay Jain, Exhibit PW-1/20, Kuldip Singh v., Chander Jain, DLT599, R.C. Chopra, Mathias v. Accor Economy Lodging Inc., Emphasis Supplied, Defendant, Emphasis Supplied, Heels, V.K Abrol, Anr, para 46(c

CARDINAL: 1, 9.5.2016, 1, 13, 9.5.2016, 10, one, 360880, 5, two, 1858.6, over 30, 2, 13, IN20393, 2, 3, 13, one, 2, 4, 13, 7, 455, 155, 45, 7, 5, 13 approximately 50, 18, 6, 13, No.2, No.2, 7, 13, 8, 13, 1/19, 9, 13 26, 7, 29, 30, 116, 5, 10, 13, 5, 8, 347, 672, one, only half, 5, 30, 36, 22, 11, 13, 11, 12, 13, 3, 2, 2, 13, 13

GPE: Ireland, IN20393, India, America, Australia, New Zealand, Japan, India, N-(2, myeloid, Philadelphia, N-(2, IN20393, India, India, India, India, India, New Delhi, DCGI, IN20393, CS(OS

FAC: Hinterbergstrasse 16

PRODUCT: No.1, No.1, No.1, No.1, Plaintiff No.1, IN20393, Punitive

ORDINAL: first, first, 4th, third, third, 3rd, third, third, 7th

NORP: Indian, Indian, Indian, Indian, Indian, Indian, Indian, Sprycel, Linkedin, Indian

MONEY: nearly $260 million

WORK_OF_ART:  Declaration